<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Stomach cancer elective surgery morbidity and mortality at 90-Day (Hold Study)</dc:title><dc:creator>Neves-Marques,	Claudia	(Avtor)
	</dc:creator><dc:creator>Abulazayem,	Mohamed	(Avtor)
	</dc:creator><dc:creator>Wong,	Geoffrey Yuet Mun	(Avtor)
	</dc:creator><dc:creator>Maldonado,	Ricardo David	(Avtor)
	</dc:creator><dc:creator>Viswanath,	Yirupaiahgari	(Avtor)
	</dc:creator><dc:creator>Grosek,	Jan	(Avtor)
	</dc:creator><dc:creator>Košir,	Jurij Aleš	(Avtor)
	</dc:creator><dc:creator>Tomažič,	Aleš	(Sodelavec pri raziskavi)
	</dc:creator><dc:subject>gastric cancer</dc:subject><dc:subject>elective surgery</dc:subject><dc:subject>morbidity</dc:subject><dc:subject>mortality</dc:subject><dc:subject>90-day postoperative outcomes</dc:subject><dc:subject>multinational audit</dc:subject><dc:subject>surgical complications</dc:subject><dc:subject>anastomotic leaks</dc:subject><dc:subject>patient safety</dc:subject><dc:description>Background: Data on multinational 90-day mortality and morbidity rates after surgery for gastric cancer is limited in the literature. This study aimed to understand the 90-day mortality and morbidity outcomes among patients undergoing elective gastric cancer surgery, as in the GASTRODATA Registry, and to identify associated risk factors. Methods: We conducted an international prospective study on patients aged ≥ 18 years undergoing elective surgery for gastric cancer with curative intent from January 4 to September 30, 2022. Known metastatic disease, concurrent secondary cancers, gastrointestinal stromal tumour (GIST) and Siewert type I/II oesophagogastric junction malignancies were excluded. Univariate and multivariate logistic regression were used to identify variables associated with the 90-day outcome. Results: 380 collaborators from 47 countries submitted data on 1538 patients. Median age was 65 years (IQR: 19–94), and 58.5% were males. 90-day morbidity and mortality rates were 38.2% (n = 587) and 2.9% (n = 45), respectively. Pre-operative higher Charlson Comorbidity Index, higher ASA score, pre-operative weight loss &gt; 10%, positive specimen margin, and post-operative pathological IV staging (p value &lt; 0.05) were significantly associated with clinically relevant complications and mortality. Conclusion: Elective gastric cancer surgery has a 90-day morbidity of 38.2% and a 90-day mortality of 2.9% globally. This study provided the most comprehensive international 90-day prospective data to date regarding gastric cancer surgery. Several factors associated with higher morbidity were identified, highlighting the importance of a unified language on surgical morbidity, prehabilitation, and ongoing audits to enhance patient outcomes.</dc:description><dc:date>2026</dc:date><dc:date>2025-12-16 12:21:53</dc:date><dc:type>Neznano</dc:type><dc:identifier>24735</dc:identifier><dc:identifier>UDK: 616.3</dc:identifier><dc:identifier>ISSN pri članku: 1435-2451</dc:identifier><dc:identifier>DOI: 10.1007/s00423-025-03890-7</dc:identifier><dc:identifier>COBISS_ID: 257716995</dc:identifier><dc:language>sl</dc:language></metadata>
